A 28-year-old woman with opioid use disorder is on methadone maintenance therapy (60 mg daily) for 3 months. She reports persistent depressed mood, anhedonia, and poor sleep. She denies active opioid use (urine drug screen negative for opioids). What is the most appropriate next step in management?

Explanation

## Comorbid Depression in Opioid Use Disorder on Maintenance Therapy **Key Point:** Depressive symptoms in a patient on stable methadone maintenance are often due to comorbid major depressive disorder (MDD), not inadequate opioid dosing. These require independent psychiatric assessment and antidepressant treatment. ### Why Assess for MDD Independently 1. **Methadone does not treat depression**: While opioids have acute euphoric effects, chronic methadone maintenance is not an antidepressant. Increasing the dose will not resolve MDD and risks overdose. 2. **High comorbidity**: 30–50% of patients with opioid use disorder have comorbid MDD, which may emerge or worsen during abstinence from illicit opioids. 3. **Negative symptoms are not withdrawal**: The patient has a negative UDS (no illicit opioid use), so depressive symptoms reflect underlying psychiatric illness, not opioid withdrawal or inadequate dosing. ### Management Algorithm for Comorbid Depression ```mermaid flowchart TD A[Patient on methadone with depressive symptoms]:::outcome --> B[UDS negative for opioids?]:::decision B -->|Yes| C[Assess for MDD using DSM-5 criteria]:::action B -->|No| D[Increase methadone dose]:::action C --> E{MDD confirmed?}:::decision E -->|Yes| F[Initiate SSRI + continue methadone]:::action E -->|No| G[Psychosocial interventions, sleep hygiene]:::action F --> H[Monitor for drug interactions & efficacy]:::action D --> H ``` ### Antidepressant Choice in Methadone Patients | Antidepressant | Advantage | Caution | |---|---|---| | **SSRI (sertraline, escitalopram)** | First-line; minimal interaction with methadone | Monitor QT interval (citalopram >20 mg/day contraindicated) | | **Tricyclic (amitriptyline)** | Effective; also helps neuropathic pain | Risk of overdose in impulsive patients; anticholinergic effects | | **SNRI (venlafaxine)** | Effective for anxiety + depression | Mild serotonin syndrome risk; monitor BP | | **Bupropion** | No sexual dysfunction; stimulating | Lowers seizure threshold; avoid in polysubstance users | **High-Yield:** SSRIs are preferred in opioid use disorder because they have minimal pharmacokinetic interaction with methadone and are safe in overdose. **Clinical Pearl:** Depressive symptoms often improve 4–6 weeks after starting an SSRI, even in patients on stable methadone. This supports the diagnosis of comorbid MDD rather than opioid-related dysphoria. **Warning:** Do NOT increase methadone dose for depression — this risks respiratory depression, overdose, and perpetuates the false belief that opioids treat mood disorders.